Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by F. Furfaro
Letter: Immunogenicity of Infliximab Originator vs. CT-P13 in IBD Patients
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Related publications
Letter: Immunogenicity of Infliximab Originator vs. CT-P13 in IBD Patients-Authors’ Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Letter: Immunogenicity of Anti-TNF in Elderly IBD Patients
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Editorial: Antigenic Response to CT-P13 and Infliximab Originator in IBD Shows Similar Epitope Recognition-Evidence From Basic Science Supports Safe Switching to Biosimilars. Authors’ Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Letter: Immunogenicity of Anti-TNF in Elderly IBD Patients-Authors' Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
PWE-102 Infective Diarrhoea Complicating Ibd vs Non-Ibd Patients
Gut
Gastroenterology
Editorial: CT-P13, a Biosimilar of Anti-Tumour Necrosis Factor-Alpha Agent (Infliximab), in Inflammatory Bowel Diseases
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Letter: New Thresholds Need to Be Defined When Using Point of Care Assays to Monitor Infliximab Trough Levels in IBD Patients
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Budget Impact Analysis of Biosimilar Infliximab (CT-P13) for the Treatment of Rheumatoid Arthritis in Six Central and Eastern European Countries
European Journal of Health Economics
Health Policy
Economics
Econometrics
Finance
THU0218 the Efficacy and Drug Survival of the Biosimilar Infliximab (CT-P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results From the Turkbio Registry
